Reposted from HDBuzz.net
UniQure has announced positive top-line results from its Phase I/II trial of AMT-130, a one-time gene therapy being tested in people with Huntington’s disease (HD). Topline data is a summary of the key results from a study that is released quickly after data becomes available to the company at a specified timepoint. In this update, uniQure reports that symptom progression is being significantly slowed by the drug, and the primary endpoint of the trial was met. This is the first time any drug has been shown to alter the course of HD in people in a clinical trial. HDBuzz caught up with uniQure’s Chief Medical Officer Walid Abi-Saab and CEO Matt Kapusta to get clarity for the HD community around this update. Let’s get into the details of this drug and the update uniQure have shared.
More News
Image
Induction Ceremony affirms collective duty to care and recognizes need to evolve traditions
This year, first-year pharmacy students at the Leslie Dan Faculty of Pharmacy read a new pledge of professionalism during the annual Induction into the Profession of Pharmacy Ceremony.
Read More
Image
PharmD for Pharmacists program opens new doors for clinical pharmacology scientist
Aaron Buaben reconnected with direct patient care and expanded his research skill set, preparing him for new possibilities in pharmacy profession.
Read More
Image
PharmSci grad’s experience opens doors across disciplines—from lab research to industry to health policy
Laura Bennett’s PhD research suggests Alzheimer’s-related protein could help relieve chronic pain.
Read More